Volpara Solutions supports the results of a randomized controlled trial on breast cancer screening. The findings of the DENSE trial (a study with a time-span of eight years) have been presented in the New England Journal of Medicine.\r\n\r\nVolpara Solutions, Inc., is a leading industry working on cancer screening. It has applauded the DENSE trial, the first study regarding the clinical application of breast MRI supplemental screening in women suffering from breast cancer.\r\n\r\nIn the DENSE trial, VolparaDensity Software provided by Volpara allows the Dutch researchers to objectively and automatically examine the breast density in women.\r\n\r\nThe findings of the study suggest that women with a Volpara volumetric breast density (VBD%) more than 15.5% have extremely dense breast tissue. These women belong to the densest category of BI-RADs and MRI supplemental screening can be advantageous for them.\r\n Related: New Study Shows Ovarian Cell With High-grade Cancer May Arise From Multiple Cell Types\r\nThe CEO and founder of Volpara Health Technologies Ltd., Ralph Highnam, states that the study results have shown a significant decrease in interval cancers via the application of VolparaDensity. Whereas, breast density is automatically examined by VolparaDensity, correlating to the MRI breast screening.\r\n\r\nAccording to the leading researcher of the study, Professor Carla van Gils, conducting this randomized controlled trial (DENSE trial) in a careful manner provides many benefits. It has allowed the researchers to find a method for reducing the prevalence of metastatic cancers and late-stage cancers.\r\n\r\nThe trial also helps in identifying the dense breast population with a more limited sensitivity of mammography. Among one of the various strengths of the DENSE trial, one is the volumetric and fully automated measurement of breast density.\r\n\r\nCarla van Gils has also appreciated the support of Volpara in their work over an eight-year period. The Chief Medical Officer (CMO) at Volpara Health Technologies Ltd, Dr. Monica Saini, said that due to the poor prognosis and aggressive nature, addressing interval cancers has become a main concern.\r\n\r\nDr, Saini is also a radiologist at New Zealand\u2019s breast screening program. The effort of the research team led by Professor van Gils offers a clear template explaining how VBD% used in screening can help women who are at risk of interval cancers.\r\n\r\nThese screening programs can reduce financial, physical, and emotional costs associated with breast cancer by detecting the women who require intervention. Women throughout the world can benefit from these new findings.\r\n\r\nVolpara, a supporter of the DENSE trial, helps the researcher team to meet its objective \u2013 Save Families from Cancer.\r\nAbout Volpara Solutions\r\nVolpara Solutions is a completely owned marketing and sales branch of New Zealand\u2019s Volpara Health Technologies Limited. VolparaDensity software provided by the industry is available in most of the markets where breast cancer screening is being done.\r\n\r\nIt provides automated and objective measurement of breast density by both tomosynthesis data and digital mammography.\r\n\r\nThe software is the collection of breast imaging tools that provides a personalized and quantitative measurement of density, breast positioning, breast compression, patient-specific x-ray dose, and other factors planned to offer critical understanding for breast cancer imaging. Aspen Breast is an advanced radiology reporting and patient tracking system for breast imaging.